论文部分内容阅读
目的探讨微小核糖核酸(microRNA,miRNA)-145在喉癌中的表达及其与临床病理参数、预后之间的关系。方法收集自2013年6月至2015年6月接受诊治的喉癌患者60例作为研究对象,60例均行喉癌根治术治疗,术后常规放疗和化疗,以手术获得的患者喉癌组织标本为喉癌组,以患者远离肿瘤的正常喉组织标本为对照组。用逆转录-聚合酶链反应(RT-PCR)法检测两组miRNA-145的表达情况,并根据miRNA-145的平均相对表达量≥0.89和<0.89将喉癌组分为高表达组(n=21)和低表达组(n=39),分析其与临床病理参数及预后的关系。结果喉癌组miRNA-145的相对表达量显著低于正常组织(0.89±0.26 vs 2.09±1.37,P<0.01);miRNA-145的表达与患者性别、年龄、分化程度、肿瘤部位无相关性(P均>0.05);而与是否有淋巴结转移、临床分期密切相关(P均<0.05)。miRNA-145高表达患者的无进展生存率显著高于miRNA-145低表达患者(P<0.05)。结论miRNA-145在喉癌组织中表达下调,miRNA-145的表达很可能与喉癌组织的浸润、转移以及预后有关,提示miRNA-145或可作为一种新的分子靶点用于喉癌的治疗及预后评估。
Objective To investigate the expression of microRNA (miRNA) -145 in laryngeal carcinoma and its relationship with clinicopathological parameters and prognosis. Methods Sixty patients with laryngeal cancer were selected from June 2013 to June 2015. 60 patients underwent laryngeal cancer radical mastectomy and conventional radiotherapy and chemotherapy respectively. For the laryngeal cancer group, patients with normal laryngeal tissue away from the tumor as a control group. The expression of miRNA-145 in both groups was detected by reverse transcription-polymerase chain reaction (RT-PCR). According to the average relative expression of miRNA-145≥0.89 and <0.89, = 21) and low expression group (n = 39), and analyzed its relationship with clinicopathological parameters and prognosis. Results The relative expression of miRNA-145 in laryngeal carcinoma was significantly lower than that in normal tissue (0.89 ± 0.26 vs 2.09 ± 1.37, P <0.01). There was no correlation between the expression of miRNA-145 and the gender, age, differentiation, P> 0.05). However, there was a close correlation between lymph node metastasis and clinical stage (all P <0.05). The progression-free survival of patients with high expression of miRNA-145 was significantly higher than those with low expression of miRNA-145 (P <0.05). Conclusions The expression of miRNA-145 is down-regulated in laryngeal carcinoma. The expression of miRNA-145 may be related to the invasion, metastasis and prognosis of laryngeal carcinoma, suggesting that miRNA-145 may serve as a new molecular target for laryngeal carcinoma Treatment and prognostic assessment.